HyQvia Needs Provider, Patient Education, Not Population Restrictions, Panel Says
Executive Summary
CBER’s Blood Products Advisory Committee votes in favor of communication strategies to mitigate the risks of Baxter’s primary immune deficiency treatment but not to monitor for possible adverse events associated with long-term exposure.
You may also be interested in...
Ariad’s Iclusig Cleared For European Approval By CHMP
Europe's top scientific advisory panel, CHMP, granted positive opinions for Ariad's new leukemia therapy Iclusig, Gilead's four-drug HIV therapy, Stribild and Baxter's subcutaneous IgG formulation, HyQvia, at its March 2013 meeting,
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.